- Home
- OPY vs KALV Comparison
OPY vs KALV Comparison
Compare OPY & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPY
- KALV
- Stock Information
- Founded
- OPY 1881
- KALV N/A
- Country
- OPY United States
- KALV United States
- Employees
- OPY N/A
- KALV N/A
- Industry
- OPY Investment Bankers/Brokers/Service
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- OPY Finance
- KALV Health Care
- Exchange
- OPY Nasdaq
- KALV Nasdaq
- Market Cap
- OPY 662.3M
- KALV 642.3M
- IPO Year
- OPY N/A
- KALV N/A
- Fundamental
- Price
- OPY $65.62
- KALV $11.41
- Analyst Decision
- OPY
- KALV Strong Buy
- Analyst Count
- OPY 0
- KALV 8
- Target Price
- OPY N/A
- KALV $24.83
- AVG Volume (30 Days)
- OPY 73.3K
- KALV 1.1M
- Earning Date
- OPY 07-25-2025
- KALV 07-10-2025
- Dividend Yield
- OPY 1.09%
- KALV N/A
- EPS Growth
- OPY 84.56
- KALV N/A
- EPS
- OPY 6.74
- KALV N/A
- Revenue
- OPY $1,358,354,000.00
- KALV N/A
- Revenue This Year
- OPY N/A
- KALV N/A
- Revenue Next Year
- OPY N/A
- KALV N/A
- P/E Ratio
- OPY $9.82
- KALV N/A
- Revenue Growth
- OPY 12.80
- KALV N/A
- 52 Week Low
- OPY $47.39
- KALV $7.30
- 52 Week High
- OPY $73.12
- KALV $15.50
- Technical
- Relative Strength Index (RSI)
- OPY 61.73
- KALV 37.30
- Support Level
- OPY $64.00
- KALV $11.10
- Resistance Level
- OPY $63.60
- KALV $12.63
- Average True Range (ATR)
- OPY 1.62
- KALV 0.89
- MACD
- OPY 0.18
- KALV -0.23
- Stochastic Oscillator
- OPY 79.67
- KALV 31.35
About OPY Oppenheimer Holdings Inc. (DE)
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.